Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2

Protocol: 
AAAR1925
Phase: 
II

Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2

The primary purpose of this trial is to determine whether adding investigational agents to standard initial cancer treatment with paclitaxel (with or without trastuzumab), and/or doxorubicin and cyclophosphamide, increases the probability of absence of residual disease, specifically in the breast and lymph nodes, over the standard initial chemotherapy alone. This will be measured for each biomarker signature established at trial entry, and to determine for each experimental agent used, the predictive probability of success in a subsequent phase 3 trial for each possible biomarker signature.

Are you Eligible? (Inclusion Criteria)

To be eligible for this trial patients must:
- have breast cancer and cannot already have had chemotherapy.
- be at least 18 years of age.
- not be pregnant and not become pregnant while on the trial.

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States